問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1858Cases

2024-01-01 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-01-05 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-11-01 - 2028-06-30

Phase II

Active
A Phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with daplusiran/tomligisiran followed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy (B-United)

  • Condition/Disease

    chronic hepatitis B

  • Test Drug

    Daplusiran/Tomligisiran (GSK5637608) Bepirovirsen (GSK3228836)

Participate Sites
4Sites

Recruiting4Sites

2022-01-01 - 2025-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2021-12-31 - 2025-10-01

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-01-01 - 2025-06-30

Phase III

Active
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    RSVPreF3 OA investigational vaccine

Participate Sites
7Sites

Recruiting5Sites

Terminated2Sites

2021-01-01 - 2024-12-31

Phase III

Completed
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    RSVPreF3 vaccine, placebo

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2006-04-01 - 2007-03-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-07-01 - 2022-12-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2014-06-01 - 2015-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 32 33 34 35 36 186
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB